Compare MPB & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | ACHV |
|---|---|---|
| Founded | 1868 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 726.5M |
| IPO Year | 1996 | 2018 |
| Metric | MPB | ACHV |
|---|---|---|
| Price | $34.47 | $6.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $41.00 | $14.15 |
| AVG Volume (30 Days) | 98.4K | ★ 1.3M |
| Earning Date | 10-21-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.45 | N/A |
| Revenue Next Year | $9.63 | N/A |
| P/E Ratio | $28.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.98 | $2.62 |
| 52 Week High | $39.15 | $8.64 |
| Indicator | MPB | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 37.54 |
| Support Level | $34.23 | $6.22 |
| Resistance Level | $34.82 | $6.64 |
| Average True Range (ATR) | 0.88 | 0.35 |
| MACD | -0.16 | -0.05 |
| Stochastic Oscillator | 26.48 | 25.40 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.